Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance
arcticnovartis
Tue, 10/24/2023 – 07:03
Read more a…
Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance
arcticnovartis
Tue, 10/24/2023 – 07:03
Read more a…
Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting
arcticnovartis
Mon, 10/23/2023 – 16:34
Read mo…
Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting
arcticnovartis
Mon, 10/23/2023 – 16:32
Read mo…
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
arcticnovartis
Fri, 10/20/2023 – 12:04
Read more about Novartis Kisqali® NATALEE analysis reinforces …
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
arcticnovartis
Fri, 10/20/2023 – 12:03
Read more about Novartis Kisqali® NATALEE analysis reinforces …
Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer
arcticnovartis
Thu, 10/05/2023 – 07:19
Read more about Novartis to present new oncology data at ESMO 2023 dem…
Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company
arcticnovartis
Wed, 10/04/2023 – 07:04
Read more about Novartis executes Sandoz Spin-off, completing strategic transformatio…
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
arcticnovartis
Mon, 10/02/2023 – 07:19
Read more about Novartis…
Novartis completes divestment of ‘front of eye’ ophthalmology assets
arcticnovartis
Fri, 09/29/2023 – 16:04
Read more about Novartis completes divestment of ‘front of eye’ ophthalmology assets
Divestment includes Xiidra®, on-market tre…